Gilead Sciences is buying MiroBio for $405 million. Via acquisition, Gilead will receive MiroBio's proprietary research platform and the entire portfolio of immuno-inhibitory receptor agonists. MiroBio's lead investigational antibody, MB272, is now in Phase 1 clinical trials.